NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=128606&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=128607&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Capri Holdings Limited (NYSE:CPRI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/capri-holdings-lawsuit-submission-form?prid=128608&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Sun Communities, Inc. (NYSE:SUI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sun-communities-inc-lawsuit-submission-form?prid=128609&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your TELUS International (Cda) Inc. (NYSE:TIXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/telus-international-lawsuit-submission-form?prid=128611&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Electronic Arts Inc. ("Electronic Arts Inc.") (NASDAQ:EA) concerning possible violations of federal securities laws. On January 22, 2025, EA issued a press release pre-announcing their preliminary Q3 FY25 results and announcing a guide-down from the company's prior expectations.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Micron Technology, Inc. (NASDAQ:MU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/micron-technology-inc-lawsuit-submission-form?prid=128610&wire=1 or contact Joseph E. Levi, Esq.

The semiconductor industry faces uncertainty due to U.S.-China trade tensions and the introduction of China's AI competitor, DeepSeek, impacting SOXX's short-term performance. SOXX's momentum has dropped significantly, reflecting recent economic events, but its long-term performance remains strong, warranting a hold rating for now. DeepSeek's emergence challenges OpenAI, potentially spurring innovation in AI, but raises concerns about Chinese censorship and national security.

Electric Vehicle Technology, Innovation & Sustainability OSCEOLA, AR / ACCESS Newswire / February 10, 2025 / Envirotech Vehicles, Inc. (NASDAQ:EVTV), a leading provider of electric commercial vehicles, acknowledges the recent policy changes under the Trump administration concerning the Green New Deal, electric vehicle mandates, and the $7,500 consumer vehicle credit. While these developments primarily impact the consumer EV market, EVTV remains confident in the robust growth potential of electric commercial vans, trucks, and school buses.

SPS Commerce, Inc. (NASDAQ:SPSC ) Q4 2024 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Irmina Blaszczyk - Investor Relations Chad Collins - Chief Executive Officer Kim Nelson - Executive Vice President & Chief Financial Officer Conference Call Participants George Kurosawa - Citi Dylan Becker - William Blair Lachlan Brown - Redburn Atlantic Parker Lane - Stifel Joe Vruwink - Baird William Jellison - D.A. Davidson Jeff Van Rhee - Craig-Hallum Quinton Gabrielli - Piper Sandler Mark Schappel - Loop Capital Markets Nehal Chokshi - Northland Capital Markets Operator Good day and welcome to the SPS Commerce …

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Electronic Arts Inc. (NASDAQ: EA) resulting from allegations that EA may have issued materially misleading business information to the investing public. So What: If you purchased EA securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=128604&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Innovative Industrial Properties, Inc. (NYSE:IIPR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/innovative-industrial-properties-inc-lawsuit-submission-form?prid=128605&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Crocs, Inc. (NASDAQ: CROX) between November 3, 2022 and October 28, 2024, inclusive (the "Class Period"), of the important March 24, 2025 lead plaintiff deadline. So what: If you purchased Crocs common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WisdomTree's U.S. LargeCap ETF has high ratings from Morningstar and Lipper Leaders, but its returns are mediocre compared to the S&P 500. The WisdomTree Large Cap Index, which EPS tracks, includes 500 large U.S. companies but underperforms in profit generation and risk control. Despite its quantitative weighting method, EPS shows no significant advantage over the overall market, with a notable tracking error of 23 basis points annually.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Affirm reported strong Q2 results, with 47% YoY revenue growth and a GAAP EPS of $0.23, significantly above expectations, demonstrating profitability and market leadership. Despite a premium valuation, Affirm's exceptional execution, market-leading growth, and profitability support a bullish outlook, though valuation concerns temper enthusiasm slightly. Key risks include intense competition, potential credit quality downturns, and the high premium valuation.

Evaluating iShares U.S. Utilities ETF as an investment option, focusing on U.S. utilities like electricity, gas, water, and waste management services. Other cyclical sectors, such as Technology, Consumer Discretionary, and Industrials are more expensive, making Utilities a potential value play. Climate and political risks are present, but I believe the potential value here outweighs those risks. I am shifting my rating on IDU to "buy."

Gold (XAUUSD) price surged to a fresh record past $2,900 Monday as President Trump announced 25% tariffs on steel and aluminum imports and investors brace for inflation data later this week.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.